Surrozen’s (SRZN) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Surrozen (NASDAQ:SRZN) in a research note released on Tuesday,Benzinga reports. The brokerage currently has a $40.00 target price on the stock.

A number of other analysts also recently weighed in on SRZN. Weiss Ratings restated a “sell (d-)” rating on shares of Surrozen in a research note on Thursday, January 22nd. Wall Street Zen upgraded Surrozen to a “sell” rating in a research report on Friday, November 28th. Finally, HC Wainwright reissued a “buy” rating and issued a $36.00 target price (up from $32.00) on shares of Surrozen in a report on Tuesday. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $38.00.

Surrozen Stock Up 7.1%

Shares of NASDAQ:SRZN opened at $28.00 on Tuesday. Surrozen has a 52 week low of $5.90 and a 52 week high of $29.59. The company has a 50-day moving average price of $24.50 and a 200 day moving average price of $18.87. The company has a market cap of $239.96 million, a P/E ratio of -0.84 and a beta of 0.53.

Surrozen (NASDAQ:SRZN) last released its earnings results on Monday, March 23rd. The company reported ($7.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.29) by ($6.30). The business had revenue of $0.53 million for the quarter, compared to analyst estimates of $0.66 million. Surrozen had a negative return on equity of 1,240.42% and a negative net margin of 7,476.67%. Analysts expect that Surrozen will post -8.49 EPS for the current year.

Insider Buying and Selling at Surrozen

In related news, major shareholder Tcg Crossover Gp Ii, Llc purchased 106,658 shares of Surrozen stock in a transaction dated Tuesday, March 24th. The stock was bought at an average cost of $24.69 per share, for a total transaction of $2,633,386.02. Following the transaction, the insider owned 736,554 shares in the company, valued at approximately $18,185,518.26. The trade was a 16.93% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Group Gp Lp Column III purchased 18,052 shares of the firm’s stock in a transaction dated Tuesday, January 20th. The shares were purchased at an average cost of $19.60 per share, for a total transaction of $353,819.20. Following the purchase, the insider directly owned 1,016,658 shares in the company, valued at approximately $19,926,496.80. This represents a 1.81% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders purchased 330,291 shares of company stock valued at $7,478,785. Corporate insiders own 45.18% of the company’s stock.

Hedge Funds Weigh In On Surrozen

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Braidwell LP purchased a new stake in Surrozen during the second quarter worth $1,252,000. Stempoint Capital LP increased its position in shares of Surrozen by 185.1% in the second quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock valued at $6,138,000 after buying an additional 445,713 shares in the last quarter. Quadrature Capital Ltd purchased a new position in shares of Surrozen in the fourth quarter valued at $335,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Surrozen during the 4th quarter worth $310,000. Finally, Ieq Capital LLC acquired a new position in shares of Surrozen during the 4th quarter worth $304,000. 66.57% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Surrozen

Here are the key news stories impacting Surrozen this week:

• Positive Sentiment: Large insider buys by major shareholder TCG Crossover GP II — the fund bought 106,658 shares on March 24 (~$24.69 avg) and has repeatedly purchased stock in March, signaling strong insider conviction that can support the share price. SEC Filing
• Positive Sentiment: Additional TCG purchase: 15,223 shares on March 23 (~$24.90 avg), a follow-on buy that reinforces the insider buying narrative. InsiderTrades article
• Positive Sentiment: HC Wainwright reiterated a “Buy”, raised multi-quarter and multi-year EPS projections (less negative) and set a $36 price target — a constructive analyst view that can attract demand. Article
• Positive Sentiment: Cantor Fitzgerald assigned an “Overweight” rating with a higher price target (reported this week), providing another institutional buy-side signal. Article
• Neutral Sentiment: Institutional ownership is high (many hedge funds hold SRZN) and several institutions increased positions in recent quarters — supportive for liquidity but not an immediate catalyst.
• Negative Sentiment: Lifesci Capital cut multiple near-term EPS estimates (Q1–Q4 2026 and FY2026), making its outlook more pessimistic and creating downside pressure for sentiment. MarketBeat coverage
• Negative Sentiment: Recent quarterly results (reported March 23) were a significant miss (EPS deeply negative vs. expectations) and the company remains loss-making with volatile margins — a fundamental risk that keeps shares speculative despite positive headlines. Earnings detail

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.